Teva reaches settlement in ProAir HFA patent case Teva Pharmaceutical announced that it has reached a settlement with Perrigo Pharmaceutical and Catalent Pharma Solutions with respect to four patents for Teva’s ProAir HFA Inhalation Aerosol product. This settlement provides a license to Perrigo and Catalent to sell limited units of Perrigo’s generic version of the product for an initial period beginning December 19, 2016 and lasting until June 2018, when the limits will no longer apply. This settlement dismisses pending litigation in the U.S. District Court for the District of Delaware in which Teva filed suit against Perrigo and Catalent in response to a notice of the filing of an ANDA containing a paragraph certification directed against four of the five patents listed in the Orange Book for ProAir HFA. Additional terms of the settlement are agreed by the parties to remain undisclosed. There are currently no additional challenges to the IP for ProAir HFA and no further litigation pending. Teva will continue to vigorously defend its intellectual property rights relating to its products.